EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease

Andrea Caddeo, Stefano Romeo

Clinical and Molecular Hepatology · 28.02.2025 · 31 (Suppl) · S76-S93

DOI: 10.3350/cmh.2024.0438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2025. Verfasst von Andrea Caddeo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Precision Medicine, Fatty Liver. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex multifactorial disease and becoming the leading cause of liver-related morbidity and mortality. MASLD spans from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), that may progress to cirrhosis and hepatocellular carcinoma (HCC). Genetic, metabolic, and environmental factors strongly contribute to the heterogeneity of MASLD. Lifestyle intervention and weight loss represent a viable treatment for MASLD. Moreover, Resmetirom, a thyroid hormone beta receptor agonist, has recently been approved for MASLD treatment. However, most individuals treated did not respond to this therapeutic, suggesting the need for a more tailored approach to treat MASLD. Oligonucleotide-based therapies, namely small-interfering RNA (siRNA) and antisense oligonucleotide (ASO), have been recently developed to tackle MASLD by reducing the expression of genes influencing MASH progression, such as PNPLA3 and HSD17B13. Here, we review the latest progress made in the synthesis and development of oligonucleotide-based agents targeting genetic determinants of MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineFatty LiverHumansOligonucleotides, AntisenseRNA, Small InterferingLipaseMembrane ProteinsAcyltransferasesPhospholipases A2, Calcium-Independent

Stichwörter der Autor:innen

ASOMAFLDMASHNAFLDsiRNA

Substanzen

Oligonucleotides, AntisenseRNA, Small InterferingLipaseMembrane ProteinsPNPLA3 protein, humanAcyltransferasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy.
  • Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.
  • Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Medicine, Endocrinology (H7) Karolinska Institute and Hospital, Huddinge, Stockholm, Sweden.

Zitieren

APA

Caddeo, A., & Romeo, S. (2025). Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clinical and Molecular Hepatology, 31(Suppl), S76-S93. https://doi.org/10.3350/cmh.2024.0438

Vancouver

Caddeo A, Romeo S. Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clinical and Molecular Hepatology. 2025;31(Suppl):S76-S93. doi:10.3350/cmh.2024.0438

BibTeX
@article{Caddeo2025,
  author = {Caddeo, Andrea and Romeo, Stefano},
  title = {Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {Suppl},
  pages = {S76--S93},
  doi = {10.3350/cmh.2024.0438}
}
Kostenlos starten →